Latuda and Encephalopathy - a phase IV clinical study of FDA data

Summary:

Encephalopathy is reported as a side effect among people who take Latuda (lurasidone hydrochloride), especially for people who are female, 40-49 old, have been taking the drug for 1 - 2 years also take Opsumit, and have Primary pulmonary hypertension.

The phase IV clinical study analyzes which people have Encephalopathy when taking Latuda. It is created by eHealthMe based on reports of 20,677 people who have side effects when taking Latuda from the FDA, and is updated regularly.

What is Latuda?

Latuda has active ingredients of lurasidone hydrochloride. It is often used in bipolar disorder. eHealthMe is studying from 21,543 Latuda users. Check the latest studies of Latuda.

What is Encephalopathy?

Encephalopathy (functioning of the brain is affected by some agent or condition) is found to be associated with 1,459 drugs and 1,606 conditions by eHealthMe. Check the latest studies of Encephalopathy.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

20,677 people reported to have side effects when taking Latuda.
Among them, 13 people (0.06%) have Encephalopathy.

Among these 13 people:

How long have people been on Latuda when they have Encephalopathy? *

What is the gender of people who have Encephalopathy when taking Latuda? *

female: 53.85 %
male: 46.15 %

What is the age of people who have Encephalopathy when taking Latuda? *

What are other drugs people take besides Latuda? *

What are other side effects people have besides Encephalopathy? *

Acute Respiratory Failure: 5 people, 38.46%
Fatigue (feeling of tiredness): 5 people, 38.46%
Fibrin D Dimer Increased: 4 people, 30.77%
Confusional State: 4 people, 30.77%
Hypokalemia (low potassium): 3 people, 23.08%
Hypophosphataemia (electrolyte disturbance in which there is an abnormally low level of phosphate in the blood): 3 people, 23.08%
Oxygen Saturation Decreased: 3 people, 23.08%
Overdose: 3 people, 23.08%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 3 people, 23.08%
Mental Disorder (a psychological term for a mental or behavioural pattern or anomaly that causes distress or disability): 3 people, 23.08%

What are the existing conditions these people have? *

Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 3 people, 23.08%
Irritability: 2 people, 15.38%
Schizophrenia (a mental disorder characterized by a breakdown of thought processes): 1 person, 7.69%
Schizoaffective Disorder (a mental disorder characterized by disordered thought): 1 person, 7.69%
Major Depression (a mood state that goes well beyond temporarily feeling sad or blue. it is a serious medical illness that affects one's thoughts, feelings): 1 person, 7.69%
Catatonia (unresponsive to external stimuli): 1 person, 7.69%
Bipolar I Disorder (mood disorder that is characterized by at least one manic or mixed episode): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Latuda and have Encephalopathy?

- Check whether Encephalopathy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Latuda:

Latuda (21,543 reports)

Encephalopathy treatments and more:

Encephalopathy (27,832 reports)

Browse all side effects of Latuda:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Encephalopathy:

Encephalopathy (1,459 drugs)

Browse all the conditions that are associated with Encephalopathy:

Encephalopathy (1,606 conditions)

Related publications that referenced our studies

Reddy, B., Das, S., & Ali, M. , "A Case of Hypersexuality Probably Associated With Lurasidone", Journal of clinical psychopharmacology, 2018 Jan .
Sood S, "Neutropenia with Multiple Antipsychotics Including Dose Dependent Neutropenia with Lurasidone", Clinical Psychopharmacology and Neuroscience, 2017 Jan .
Kapoor A, Kumar V, Beniwal S, Dutta S, Goyal S, Kumar HS, "Posterior reversible encephalopathy syndrome in non-Hodgkin's lymphoma: Not necessarily reversible!", Clinical Cancer Investigation Journal, 2015 Mar .
Reddy, B., Das, S., & Ali, M. , "A Case of Hypersexuality Probably Associated With Lurasidone", Journal of clinical psychopharmacology, 2018 Jan .
Sood S, "Neutropenia with Multiple Antipsychotics Including Dose Dependent Neutropenia with Lurasidone", Clinical Psychopharmacology and Neuroscience, 2017 Jan .
Kapoor A, Kumar V, Beniwal S, Dutta S, Goyal S, Kumar HS, "Posterior reversible encephalopathy syndrome in non-Hodgkin's lymphoma: Not necessarily reversible!", Clinical Cancer Investigation Journal, 2015 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on lurasidone hydrochloride (the active ingredients of Latuda) and Latuda (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.